返回
Multiple Myeloma, Version 5.2026
DOI:10.6004/jnccn.2026.0001.png)
摘要
En 中文
The treatment landscape for multiple myeloma (MM) is evolving rapidly and includes several new options. The management must be tailored to the individual. The NCCN Guidelines for MM provide a framework to base decisions regarding diagnosis, workup, treatment, and follow-up of both newly diagnosed and previously treated relapsed/refractory MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to newly diagnosed MM (NDMM).
Keyword:
STEM-CELL TRANSPLANTATION
DONOR LYMPHOCYTE INFUSIONS
POSITRON-EMISSION-TOMOGRAPHY
MINIMAL RESIDUAL DISEASE
HIGH-DOSE THERAPY
DEXAMETHASONE INDUCTION THERAPY
MULTIPARAMETER FLOW-CYTOMETRY
INTERNATIONAL STAGING SYSTEM
NEWLY-DIAGNOSED MYELOMA
RANDOMIZED PHASE-III
期刊
J
IF:
16.4
论文数:
2.8K
被引数:
1.5W
机构
引用论文
暂无论文信息



